The use of denosumab in giant cell tumors in the sacrum

Giant Cell Tumor (GCT), a benign tumor with local aggression, corresponds to 5% of primary tumors. Fifteen percent of these are located in the sacrum. En bloc resection is an effective treatment, but when it cannot be performed, Denosumab may be indicated as an alternative treatment. The objectives...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bazán, Pedro Luis, Di Falco, Renata, Borri, Álvaro Enrique, Medina, Martín, Ciccioli, Nicolás Maximiliano, Danelle, Sergio
Formato: Articulo
Lenguaje:Español
Publicado: 2020
Materias:
Ciencias Médicas
Giant Cell Tumor of Bone
Sacral Region
Denosumab
Complications
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/108842
Aporte de:
SEDICI (UNLP) de Universidad Nacional de La Plata
id I19-R120-10915-108842
record_format dspace
institution Universidad Nacional de La Plata
institution_str I-19
repository_str R-120
collection SEDICI (UNLP)
language Español
topic Ciencias Médicas
Giant Cell Tumor of Bone
Sacral Region
Denosumab
Complications
spellingShingle Ciencias Médicas
Giant Cell Tumor of Bone
Sacral Region
Denosumab
Complications
Bazán, Pedro Luis
Di Falco, Renata
Borri, Álvaro Enrique
Medina, Martín
Ciccioli, Nicolás Maximiliano
Danelle, Sergio
The use of denosumab in giant cell tumors in the sacrum
topic_facet Ciencias Médicas
Giant Cell Tumor of Bone
Sacral Region
Denosumab
Complications
description Giant Cell Tumor (GCT), a benign tumor with local aggression, corresponds to 5% of primary tumors. Fifteen percent of these are located in the sacrum. En bloc resection is an effective treatment, but when it cannot be performed, Denosumab may be indicated as an alternative treatment. The objectives of this work are: to justify the indication; determine the best dose and time of use; and recognize the need for posttreatment surgery. Methods: A systematic search of clinical trials. Twenty-five articles were selected, ten of which met the inclusion criteria. The use of Denosumab is justified in advanced stages, with a dose of 120 mg administered subcutaneously, every 7 days in the first month and then maintained every 4 weeks, for 2.5 to 13 months. Adverse events are mild and can be observed in 84% of patients. With Denosumab, surgery may be less aggressive or even unnecessary. The bibliography justifies the indication of Denosumab in advanced stages of GCT, with a dose of 120 mg administered subcutaneously; there is no consensus as to the maintenance dose, which is a weekly dose in the first month and then every four weeks for 2.5 to 13 months. Complications are frequent but mild. Level of evidence III; Systematic review.
format Articulo
Articulo
author Bazán, Pedro Luis
Di Falco, Renata
Borri, Álvaro Enrique
Medina, Martín
Ciccioli, Nicolás Maximiliano
Danelle, Sergio
author_facet Bazán, Pedro Luis
Di Falco, Renata
Borri, Álvaro Enrique
Medina, Martín
Ciccioli, Nicolás Maximiliano
Danelle, Sergio
author_sort Bazán, Pedro Luis
title The use of denosumab in giant cell tumors in the sacrum
title_short The use of denosumab in giant cell tumors in the sacrum
title_full The use of denosumab in giant cell tumors in the sacrum
title_fullStr The use of denosumab in giant cell tumors in the sacrum
title_full_unstemmed The use of denosumab in giant cell tumors in the sacrum
title_sort use of denosumab in giant cell tumors in the sacrum
publishDate 2020
url http://sedici.unlp.edu.ar/handle/10915/108842
work_keys_str_mv AT bazanpedroluis theuseofdenosumabingiantcelltumorsinthesacrum
AT difalcorenata theuseofdenosumabingiantcelltumorsinthesacrum
AT borrialvaroenrique theuseofdenosumabingiantcelltumorsinthesacrum
AT medinamartin theuseofdenosumabingiantcelltumorsinthesacrum
AT cicciolinicolasmaximiliano theuseofdenosumabingiantcelltumorsinthesacrum
AT danellesergio theuseofdenosumabingiantcelltumorsinthesacrum
AT bazanpedroluis ousodedenosumabemtumoresdecelulasgigantesnosacro
AT difalcorenata ousodedenosumabemtumoresdecelulasgigantesnosacro
AT borrialvaroenrique ousodedenosumabemtumoresdecelulasgigantesnosacro
AT medinamartin ousodedenosumabemtumoresdecelulasgigantesnosacro
AT cicciolinicolasmaximiliano ousodedenosumabemtumoresdecelulasgigantesnosacro
AT danellesergio ousodedenosumabemtumoresdecelulasgigantesnosacro
AT bazanpedroluis elusodedenosumabeneltumordecelulasgigantesenelsacro
AT difalcorenata elusodedenosumabeneltumordecelulasgigantesenelsacro
AT borrialvaroenrique elusodedenosumabeneltumordecelulasgigantesenelsacro
AT medinamartin elusodedenosumabeneltumordecelulasgigantesenelsacro
AT cicciolinicolasmaximiliano elusodedenosumabeneltumordecelulasgigantesenelsacro
AT danellesergio elusodedenosumabeneltumordecelulasgigantesenelsacro
AT bazanpedroluis useofdenosumabingiantcelltumorsinthesacrum
AT difalcorenata useofdenosumabingiantcelltumorsinthesacrum
AT borrialvaroenrique useofdenosumabingiantcelltumorsinthesacrum
AT medinamartin useofdenosumabingiantcelltumorsinthesacrum
AT cicciolinicolasmaximiliano useofdenosumabingiantcelltumorsinthesacrum
AT danellesergio useofdenosumabingiantcelltumorsinthesacrum
bdutipo_str Repositorios
_version_ 1764820444055076868

Ejemplares similares